SS-31 – (736992-21-5)

Elamipretide, also known as SS-31, MTP-131, and Bendavia, is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that has shown promise in reducing the production of toxic reactive oxygen species (ROS) and stabilizing cardiolipin, a key component of the inner mitochondrial membrane. Developed by Stealth BioTherapeutics, elamipretide has been investigated for its potential in treating a variety of conditions related to mitochondrial dysfunction.

The peptide’s mechanism of action involves enhancing cellular ATP synthesis, improving electron transport, and reducing ROS formation, without negatively affecting healthy mitochondria. This makes it a potential therapeutic agent for diseases where mitochondrial dysfunction plays a critical role, such as heart failure, kidney injury, and neurodegenerative disorders.

In clinical trials, elamipretide has been studied for its efficacy in treating mitochondrial myopathy, with a Phase III trial initiated in 2017. However, as of January 2020, the trial did not meet its expected outcomes. Despite this setback, the peptide continues to be researched for its neuroprotective properties, particularly in the context of traumatic optic neuropathy (TON). Studies have shown that elamipretide, when administered in conjunction with TNF inhibitors like etanercept, can significantly improve retinal ganglion cell (RGC) survival following optic nerve trauma.

Elamipretide’s ability to mitigate oxidative stress and inflammation has also been demonstrated in animal models of cognitive impairment and myocardial infarction. For instance, in a mouse model of lipopolysaccharide-induced cognitive impairment, elamipretide was found to protect the hippocampus from mitochondrial dysfunction and attenuate oxidative stress and inflammatory responses.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Elamipretide, also known as SS-31, MTP-131, and Bendavia, is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that has shown promise in reducing the production of toxic reactive oxygen species (ROS) and stabilizing cardiolipin, a key component of the inner mitochondrial membrane. Developed by Stealth BioTherapeutics, elamipretide has been investigated for its potential in treating a variety of conditions related to mitochondrial dysfunction.

The peptide’s mechanism of action involves enhancing cellular ATP synthesis, improving electron transport, and reducing ROS formation, without negatively affecting healthy mitochondria. This makes it a potential therapeutic agent for diseases where mitochondrial dysfunction plays a critical role, such as heart failure, kidney injury, and neurodegenerative disorders.

In clinical trials, elamipretide has been studied for its efficacy in treating mitochondrial myopathy, with a Phase III trial initiated in 2017. However, as of January 2020, the trial did not meet its expected outcomes. Despite this setback, the peptide continues to be researched for its neuroprotective properties, particularly in the context of traumatic optic neuropathy (TON). Studies have shown that elamipretide, when administered in conjunction with TNF inhibitors like etanercept, can significantly improve retinal ganglion cell (RGC) survival following optic nerve trauma.

Elamipretide’s ability to mitigate oxidative stress and inflammation has also been demonstrated in animal models of cognitive impairment and myocardial infarction. For instance, in a mouse model of lipopolysaccharide-induced cognitive impairment, elamipretide was found to protect the hippocampus from mitochondrial dysfunction and attenuate oxidative stress and inflammatory responses.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Elamipretide
https://pubchem.ncbi.nlm.nih.gov/#query=736992-21-5
https://www.medchemexpress.com/Elamipretide.html
https://www.medkoo.com/products/6723
https://pmc.ncbi.nlm.nih.gov/articles/PMC7554259/
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/elamipretide
Other Names

MTP-131, Elamipretide

IUPAC Name

(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2, 6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide

CAS

736992-21-5

Molecular Weight

639.8

Molecular Formula

C32H49N9O5

SMILES

CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)N)C)O

No products in the cart.